An anti-obesity effect was observed for cholest-4-en-3-one (cholestenone) which is an intestinal catabolite of cholesterol. Body weight gain and body fat accumulation of CDF1 mice were inhibited by 0.5% dietary exposure to this chemical. Dose response for the effect of cholestenone was found to increase as the dose rose from 0.1 to 0.3% and 0.5%. No obvious anomaly due to consumption of cholestenone was detected by necropsy and clinical observation. The mechanism of this effect of cholestenone is not known at present, but it was not due to anorexia.
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Results. In experiment 1, control and cholesterol-fed mice grew rapidly as shown in Fig. 1 . They showed signs of obesity after consumption of either the control or cholesterol diet for 4months in males or 6months in females. However, mice fed cholestenone did not show any signs of obesity even when fed the diet for 17months. The differences between the body weight of the cholestenone group and the other groups were statistically significant at the <0.001 level. In this case, body weights in cholestenone-fed male mice were almost equal to values obtained for male CDF1 mice fed a standard stock feed (type CE-2, CLEA Japan Inc.; calories, 1,435 kJ; fat, 4.4%; protein, 25.1%; NFE, 50.9%) for 4months reported by Morisada et al. (10) . Body weights of mice fed cholesterol were similar to those of the control mice. Body weights of the cholestenone-fed mice were 85% (males) and 87% (females) of those of the control mice at 8months of age. Cholestenone fed mice did not show any clinical signs of abnormalities such as coat roughness, weakness, or diarrhea.
As shown in Fig. 2 , the amounts of adipose tissue in the abdominal cavity of the cholestenone fed mice were about 1/3 (males) or 1/2 (females) of those of the control and cholesterol-fed mice. A preliminary examination also showed major Figs. 3 and 4 . Total cholesterol and phospholipid concentrations of the cholestenone-fed mice were significantly higher than those of the control mice for female mice, but not for male mice. A decreasing tendency in the amounts of triglyceride and lipoproteins, especially chylomicron, was observed in the cholestenone group. Survival rates and the tumor incidences in 18-month-old mice were not affected by the feeding of cholestenone and cholesterol. All animals showed high incidences of small intesti nal polyposis at levels of 37% in females and 54% in males. There were few differences in the weights of the brain, lung, heart, liver, kidneys, spleen, testes (or ovaries), pituitary gland, and adrenal glands among the groups (data not shown).
The dose response for the body weight of CDF1 mice is shown in Fig. 5 . Proportional inhibition of body weight by cholestenone feeding was observed with the 0.1, 0.3, and 0.5% doses. The variance among values in the experimental groups was statistically significant (p<0.001). As shown in Table 1 , no significant difference was obtained for cumulative feed intake per mouse in each experimental group. All animals showed healthy growth without clinical abnormalities.
Discussion. The results of our study showed that cholestenone, an intestinal catabolite of cholesterol, prevents diet-induced obesity by dietary exposure without any clinical abnormalities. Dose response was recognized for this anti-obesity effect of cholestenone. Since weights of major internal organs and the hormonal glands, survival rate, tumor incidence, and clinical observations generally showed little change after consumption of cholestenone for 17months, it appeared that cholest enone had very weak toxicity and carcinogenicity in test animals . The high incidence of small intestinal polyposis in all experimental mice was thought to be inherited since Mizutani et al. (11) reported that BALB/c mice , a maternal line of CDF1 mice, showed high incidences of small intestinal polyposis at levels of 37% in females and 51% in males at 12months of age . It is obvious that the effect of cholestenone on body-weight loss of mice was not due to taste aversion for feed as observed from the feed intake and spillage of test mice . This is also evident from the characteristics of this chemical , i.e., insoluble in water and forms stable, achromatic, tasteless, and odorless crystals at normal temperature (12) . The above data regarding the anti-obesity effect of cholestenone are still not sufficient to indicate the mode of action of the chemical , but several speculations exist on why cholestenone feeding leads to inhibition of body fat accumulation . First, it is accepted that cholesterol and cholestenone are typical representatives of membrane active and inactive steroids, respectively (13) . If cholestenone hinders the formation of lipoprotein membrane in an antagonistic manner to cholesterol , triglyceride transportation with lipoprotein may be reduced . Secondly, cholesten one feeding to rats results in adrenal hypertrophy and suppression of adrenal steroid secretion (14) . This suppression of corticosteroids should then be reflected in inhibition of synthesis of fatty acids in the liver . However, our experiment using mice showed no hypertrophy of the adrenal glands in spite of long-term feeding of cholestenone.
Further work is necessary to substantiate the mechanism of the effect of cholestenone. Analysis of cholesterol and cholestenone contents in lipoprotein membrane and corticosteroids concentration in the adrenal glands should provide information on the mode of action of this cholesterol metabolite . Measurement of fecal lipid for excreted energy content and histological examination of the intestinal villi and the liver for accumulation of lipid should also indicate whether there is inhibition of fat absorption or transportation . Moreover the rate of absorption and distribution in the organs of labeled cholestenone after oral administration is necessary to assess the toxicity of this chemical . 
